Medical/Pharmaceuticals

China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer

CHENGDU, China, Sept. 22, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX:02162) announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted CMG901 the Breakthrough Therapy Designation for the treatment of advanced gastric and gastroe...

2022-09-22 13:05 1291

RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates

SINGAPORE, Sept. 21, 2022 /PRNewswire/ -- RVAC Medicines Pte. Ltd., a messenger RNA (mRNA) technology platform company incubated by CBC Group in 2021, announced today that a participant has been dosed in a Phase 1, first-in-human study evaluating the company's mRNA-based COVID-19 vaccine candidat...

2022-09-22 10:00 1610

Ascentage Pharma Announces Phase I/II Data of Olverembatinib (HQP1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-in-Class Potential

SUZHOU, China and ROCKVILLE, Md., Sept. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the results from a Phase I and Phase II study of ...

2022-09-21 22:49 1581

Lunit Showcases AI Solutions for Radiology at AOCR & KCR 2022

* Lunit participates in the 20th Asian Oceanian Congress of Radiology and 78th Annual Meeting of the Korean Society of Radiology (AOCR & KCR 2022) * Lunit's demonstration focuses on how radiologists and AI solutions can create synergy through combined workflows * Visitors invited to Lunit De...

2022-09-21 22:48 1564

United Imaging and Carrollton Regional Medical Center Accelerate Installation of the Revolutionary uCT® ATLAS Scanner

Highlights Agility of Both Organizations in Responding to Patient Needs HOUSTON, Sept. 21, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that it delivered its flagship uCT ATLAS scanner earlier than first scheduled, at the ...

2022-09-21 21:00 1208

Charsire's New Drug Aims to Capture Multi-Billion-Dollar Dementia Treatment Market

TAINAN CITY, Taiwan, Sept. 21, 2022 /PRNewswire/ -- Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease and vascular dementia using its patented technology of Multi-Glycan Complex and soybeans as raw materials. BAC has completed Phase II ...

2022-09-21 20:00 1019

Mediaseek's Proprietary Neurofeedback Engine "Alpha Switch" and Its Smartphone Application Mentioned in International Journal

- Engine and App Used in Research Paper on Chronic Low Back Pain Treatment at Pain Center of Chiba University Hospital Published in "Scientific Reports" - TOKYO, Sept. 21, 2022 /PRNewswire/ -- Mediaseek, Inc. (hereinafter referred to as "Mediaseek") based inTokyo is pleased to announce that a res...

2022-09-21 14:00 1156

GMP cell CDMO I Peace, Inc. in collaboration with universities successfully converted human dermal fibroblasts into oligodendrocyte by direct reprogramming

PALO ALTO, Calif., Sept. 20, 2022 /PRNewswire/ -- Koji Tanabe of I Peace, Inc. ( https://www.ipeace.com ) and a researcher Hiroko Nobuta of theUniversity of California, San Francisco (currently assistant professor at Rutgers University) successfully achieved the direct repr...

2022-09-21 05:39 1178

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tr...

2022-09-20 19:25 1465

Special interview with Dr. Patrick Yu-Wai-Man on International LHON Awareness Day

WUHAN, China and SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- September 19th is International LHON Awareness Day. LHON is a debilitating disease that leads to quick vision loss concomitantly or successively. It mostly impacts young adolescent males and brings tremendous physical and psychological st...

2022-09-19 20:00 2391

New treatment for rare cancer cholangiocarcinoma approved in Australia

* Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement * PEMAZYRE® (pemigatinib) is available via a co-pay access program in Australia SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- A NEW targeted therapy to treat a rare bile duct c...

2022-09-15 21:00 1514

Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance

SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for...

2022-09-15 17:07 1412

J INTS BIO, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022)

SEOUL, South Korea, Sept. 15, 2022 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' at the 2022 edition of the European Society for Medical Oncology Congress (ESMO 2022) held inParis, France from 9th to 13th September...

2022-09-15 14:12 1135

United Imaging Announces Clinical System Installations at Huntsman Cancer Institute at the University of Utah

Agreement envisions expansion of cutting-edge clinical services. HOUSTON, Sept. 14, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that TheCenter for Quantitative Cancer Imaging

2022-09-14 21:00 1408

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment ...

2022-09-14 20:30 2480

DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY

AUCKLAND, New Zealand, Sept. 14, 2022 /PRNewswire/ -- New Zealand based soft tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor, Dr.Catherine Mohr as a Non-Executive Director to the board.

2022-09-14 13:05 1298

MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS

MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center ('MD Anderson') and Radiopharm Theranostics Limited ('Radiopharm')(ASX: RAD) today announced the launch of Radiopharm Ventu...

2022-09-14 11:09 1243

New Study by Lunit and MGH Validates Effectiveness of AI as Aid in Chest X-Ray Interpretation - Published in JAMA Network Open

* Joint study with Massachusetts General Hospital proves that Lunit's AI-powered chest x-ray analysis software enhances the overall performance and efficiency of radiologists SEOUL, South Korea, Sept. 13, 2022 /PRNewswire/ -- A recent study published in

2022-09-13 22:16 1365

EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development... to "accelerate entering the overseas market"

* An expert from Invitae and Ambry Genetics, U.S. genome analysis companies * EDGC states, "We will expand the overseas genome analysis market and advance into the global liquid biopsy technology market by recruiting a global talent in the genome field" * Worked in a non-profit research orga...

2022-09-13 21:00 1612

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (...

2022-09-13 20:00 2224
1 ... 111112113114115116117 ... 215